CRISPR Therapeutics AG (CRSP)
50.07
+1.51
(+3.11%)
USD |
NASDAQ |
Nov 06, 16:00
50.00
-0.07
(-0.14%)
After-Hours: 20:00
CRISPR Therapeutics Research and Development Expense (Quarterly) : 69.79M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 69.79M |
| June 30, 2026 | 64.95M |
| March 31, 2026 | 66.37M |
| December 31, 2025 | 77.86M |
| September 30, 2025 | 54.50M |
| June 30, 2025 | 65.29M |
| March 31, 2025 | 67.75M |
| December 31, 2024 | 77.31M |
| September 30, 2024 | 77.36M |
| June 30, 2024 | 75.32M |
| March 31, 2024 | 71.34M |
| December 31, 2023 | 90.24M |
| September 30, 2023 | 85.77M |
| June 30, 2023 | 96.59M |
| March 31, 2023 | 94.88M |
| December 31, 2022 | 97.71M |
| September 30, 2022 | 150.46M |
| June 30, 2022 | 149.88M |
| March 31, 2022 | 142.85M |
| December 31, 2021 | 128.21M |
| September 30, 2021 | 100.00M |
| June 30, 2021 | 104.68M |
| March 31, 2021 | 87.86M |
| Date | Value |
|---|---|
| December 31, 2020 | 79.80M |
| September 30, 2020 | 68.67M |
| June 30, 2020 | 57.19M |
| March 31, 2020 | 52.09M |
| December 31, 2019 | 47.33M |
| September 30, 2019 | 55.96M |
| June 30, 2019 | 39.53M |
| March 31, 2019 | 33.82M |
| December 31, 2018 | 28.80M |
| September 30, 2018 | 39.82M |
| June 30, 2018 | 25.63M |
| March 31, 2018 | 19.52M |
| December 31, 2017 | 20.03M |
| September 30, 2017 | 17.84M |
| June 30, 2017 | 17.12M |
| March 31, 2017 | 14.80M |
| December 31, 2016 | 15.57M |
| September 30, 2016 | 12.05M |
| June 30, 2016 | 8.602M |
| March 31, 2016 | 6.012M |
| June 30, 2015 | 1.486M |
| March 31, 2015 | 1.164M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median